CATALYST PHARMACEUTICALS INC (CPRX)
Health Care · NASDAQ
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from established and newly approved products.
What CATALYST PHARMACEUTICALS INC does
Catalyst Pharmaceuticals develops and commercializes pharmaceutical products for rare diseases, primarily focused on neuromuscular conditions. The company markets FIRDAPSE® (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) and recently commercialized AGAMREE® (vamorolone), a novel corticosteroid for Duchenne muscular dystrophy (DMD) approved by the FDA in October 2023. The company operates through direct sales and support programs including the Catalyst Pathways® Program to assist patients in accessing therapies.
Themes: ["Duchenne muscular dystrophy (DMD)","Lambert-Eaton myasthenic syndrome","Neuromuscular disorders","Rare disease therapeutics","Pediatric rare diseases","Sarepta Therapeutics (SRPT)","Solid Biosciences (SLDB)","PTC Therapeutics (PTCT)","Atheneum Pharma","Patent litigation exposure: ongoing Paragraph IV patent challenges against FIRDAPSE® (case against Hetero scheduled for trial March 2026) could result in generic competition and erosion of exclusivity and revenue"]
Fundamentals
- Price$31.47 as of 2026-07-09 close
- Market cap$3.9B as of 2026-07-10
- 1-year return+45.5% as of 2026-07-09 close
- P/E17.41 as of 2026-07-10
- Net margin+37.1% as of 2026-07-10
- Gross margin+86.0% as of 2026-07-10
- ROE+23.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+11.7% as of 2026-07-10
- Revenue CAGR (3y)+40.1% SEC XBRL
- Beta0.78 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.